Suppr超能文献

一生中多次人体测量与前列腺癌诊断、转移及死亡情况

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.

作者信息

Gerdtsson Axel, Poon Jessica B, Thorek Daniel L, Mucci Lorelei A, Evans Michael J, Scardino Peter, Abrahamsson Per-Anders, Nilsson Peter, Manjer Jonas, Bjartell Anders, Malm Johan, Vickers Andrew, Freedland Stephen J, Lilja Hans, Ulmert David

机构信息

Department of Clinical Sciences (Urology), Lund University, Skåne University Hospital, Malmö, Sweden; Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Eur Urol. 2015 Dec;68(6):1076-82. doi: 10.1016/j.eururo.2015.03.017. Epub 2015 Mar 18.

Abstract

BACKGROUND

Previous studies of prostate cancer (PCa) risk and anthropometrics (ie, body measurements) were based on single measurements or obtained over limited time spans.

OBJECTIVE

To study the association between anthropometrics measured at multiple time points in life and their relation to later diagnosis, metastasis, or death from PCa.

DESIGN, SETTING, AND PARTICIPANTS: This case-control study includes 27 167 Swedish men enrolled in two population-based projects from 1974 to 1996. PCa diagnosis up to December 31, 2006, disease information, gestation time, and anthropometrics at birth, military conscript testing, and adulthood were collected. A total of 1355 PCa cases were matched with 5271 controls.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Univariate conditional logistic regression was used to determine whether clinical diagnosis, metastasis, or PCa death was associated with low birth weight (weight <2500 g); with small size for gestational age; or with weight, length, or body mass index (BMI) at birth, adolescence (aged 16-22 yr), or early middle age (aged 44-50 yr).

RESULTS AND LIMITATIONS

Apart from weight at adolescence, which was associated with an increased risk of PCa diagnosis (odds ratio [OR] per 5 kg: 1.05; 95% confidence interval [CI], 1.01-1.09; p=0.026), preadulthood measurements were not associated with any PCa end point. Adulthood parameters were not associated with diagnosis. In contrast, weight and BMI at early middle age were significantly associated with metastasis (OR per 5 kg: 1.13; 95% CI, 1.06-1.20; p<0.0001, and OR: 1.09; 95% CI, 1.05-1.14; p<0.0001) and death (OR per 5 kg: 1.11 (95% CI, 1.03-1.19; p=0.005, and OR: 1.08; 95% CI, 1.03-1.13; p=0.003), respectively. It remains unclear whether these results apply to men of nonwhite origin, to populations with active PCa screening programs, or to countries without socialized health care.

CONCLUSIONS

The analyses of these large data sets demonstrate that significant effects of body characteristics (with links to metabolic syndrome) measured at early middle age are associated with PCa disease severity, metastatic progression, and outcome. Conversely, measurements at birth and adolescence are not associated with PCa prevalence or outcome.

PATIENT SUMMARY

Increased weight and body mass index in adults is associated with a higher risk of prostate cancer metastasis and death.

摘要

背景

先前关于前列腺癌(PCa)风险与人体测量学(即身体测量)的研究基于单次测量或在有限时间段内获得的数据。

目的

研究在生命中多个时间点测量的人体测量学指标与随后前列腺癌诊断、转移或死亡之间的关联。

设计、地点和参与者:这项病例对照研究纳入了1974年至1996年参与两项基于人群项目的27167名瑞典男性。收集了截至2006年12月31日的前列腺癌诊断信息、疾病信息、妊娠期以及出生时、征兵体检时和成年期的人体测量数据。总共1355例前列腺癌病例与5271名对照进行匹配。

结局测量和统计分析

采用单变量条件逻辑回归来确定临床诊断、转移或前列腺癌死亡是否与低出生体重(体重<2500 g)、小于胎龄儿或出生时、青春期(16 - 22岁)或中年早期(44 - 50岁)的体重、身长或体重指数(BMI)相关。

结果与局限性

除青春期体重与前列腺癌诊断风险增加相关外(每增加5 kg的比值比[OR]:1.05;95%置信区间[CI],1.01 - 1.09;p = 0.026),成年前测量指标与任何前列腺癌终点均无关联。成年期参数与诊断无关。相反,中年早期的体重和BMI与转移(每增加5 kg的OR:1.13;95% CI,1.06 - 1.20;p < 0.0001,以及OR:1.09;95% CI,1.05 - 1.14;p < 0.0001)和死亡(每增加5 kg的OR:1.11(95% CI,1.03 - 1.19;p = 0.005,以及OR:1.08;95% CI,1.03 - 1.13;p = 0.003))分别显著相关。这些结果是否适用于非白人男性、有活跃前列腺癌筛查项目的人群或没有社会化医疗保健的国家仍不清楚。

结论

对这些大型数据集的分析表明,中年早期测量的身体特征(与代谢综合征相关)的显著影响与前列腺癌疾病严重程度、转移进展和结局相关。相反,出生时和青春期的测量与前列腺癌患病率或结局无关。

患者总结

成年人体重和体重指数增加与前列腺癌转移和死亡风险较高相关。

相似文献

1
Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.
Eur Urol. 2015 Dec;68(6):1076-82. doi: 10.1016/j.eururo.2015.03.017. Epub 2015 Mar 18.
2
Towards an optimal interval for prostate cancer screening.
Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10.
4
Metformin use and prostate cancer risk.
Eur Urol. 2014 Dec;66(6):1012-20. doi: 10.1016/j.eururo.2014.04.027. Epub 2014 May 22.
5
Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
Lipids Health Dis. 2015 Sep 17;14:111. doi: 10.1186/s12944-015-0096-0.
8
9
Physical Activity and Survival After Prostate Cancer.
Eur Urol. 2016 Oct;70(4):576-585. doi: 10.1016/j.eururo.2015.12.032. Epub 2016 Jan 7.

引用本文的文献

2
Birth weight and birth length affect future fracture risk differently in men and women.
Osteoporos Int. 2024 Oct;35(10):1817-1829. doi: 10.1007/s00198-024-07172-8. Epub 2024 Jul 5.
6
Overall and abdominal obesity and prostate cancer risk in a West African population: An analysis of the Ghana Prostate Study.
Int J Cancer. 2020 Nov 15;147(10):2669-2676. doi: 10.1002/ijc.33026. Epub 2020 May 6.
8
Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis.
Br J Cancer. 2016 Mar 29;114(7):839-48. doi: 10.1038/bjc.2016.38. Epub 2016 Mar 1.

本文引用的文献

1
Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark.
Int J Cancer. 2015 Apr 15;136(8):1940-7. doi: 10.1002/ijc.29238. Epub 2014 Oct 9.
3
Childhood height and birth weight in relation to future prostate cancer risk: a cohort study based on the copenhagen school health records register.
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2232-40. doi: 10.1158/1055-9965.EPI-13-0712. Epub 2013 Oct 2.
5
Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.
J Endocrinol Invest. 2013 Feb;36(2):132-9. doi: 10.1007/BF03346748.
6
Obesity and prostate cancer: weighing the evidence.
Eur Urol. 2013 May;63(5):800-9. doi: 10.1016/j.eururo.2012.11.013. Epub 2012 Nov 15.
7
Metabolic syndrome and risk of cancer: a systematic review and meta-analysis.
Diabetes Care. 2012 Nov;35(11):2402-11. doi: 10.2337/dc12-0336.
8
Prospective study on metabolic factors and risk of prostate cancer.
Cancer. 2012 Dec 15;118(24):6199-206. doi: 10.1002/cncr.27677. Epub 2012 Oct 22.
10
Weight change and prostate cancer incidence and mortality.
Int J Cancer. 2012 Oct 1;131(7):1711-9. doi: 10.1002/ijc.27414. Epub 2012 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验